Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01131702 | Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions | PHASE1 | COMPLETED | 24 | — | — | Jan 1, 2003 | Mar 1, 2003 | Jun 9, 2010 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Ranitidine Tablets, 300 mg | EXPERIMENTAL | Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited |
| Zantac Tablets, 300 mg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ranitidine | DRUG | Ranitidine Tablets, 300 mg |
Inclusion Criteria: * Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may be done using different media (e.g. radio, newspaper, Anapharm Inc. Web site. Anapharm Inc. volunteers' data base). Subjects must meet all of the following criteria in...